Literature DB >> 20864805

Therapeutic antibodies directed at G protein-coupled receptors.

Catherine J Hutchings1, Markus Koglin, Fiona H Marshall.   

Abstract

G protein-coupled receptors (GPCRs) are one of the most important classes of targets for small molecule drug discovery, but many current GPCRs of interest are proving intractable to small molecule discovery and may be better approached with bio-therapeutics. GPCRs are implicated in a wide variety of diseases where antibody therapeutics are currently used. These include inflammatory diseases such as rheumatoid arthritis and Crohn disease, as well as metabolic disease and cancer. Raising antibodies to GPCRs has been difficult due to problems in obtaining suitable antigen because GPCRs are often expressed at low levels in cells and are very unstable when purified. A number of new developments in over-expressing receptors, as well as formulating stable pure protein, are contributing to the growing interest in targeting GPCRs with antibodies. This review discusses the opportunities for targeting GPCRs with antibodies using these approaches and describes the therapeutic antibodies that are currently in clinical development.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20864805      PMCID: PMC3011214          DOI: 10.4161/mabs.2.6.13420

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  112 in total

Review 1.  Principles: receptor theory in pharmacology.

Authors:  Terry Kenakin
Journal:  Trends Pharmacol Sci       Date:  2004-04       Impact factor: 14.819

Review 2.  GPCR agonists and antagonists in the clinic.

Authors:  Joel D A Tyndall; Radhika Sandilya
Journal:  Med Chem       Date:  2005-07       Impact factor: 2.745

3.  Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry.

Authors:  M Farzan; T Mirzabekov; P Kolchinsky; R Wyatt; M Cayabyab; N P Gerard; C Gerard; J Sodroski; H Choe
Journal:  Cell       Date:  1999-03-05       Impact factor: 41.582

4.  Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma.

Authors:  Toshihiko Ishii; Takashi Ishida; Atae Utsunomiya; Atsushi Inagaki; Hiroki Yano; Hirokazu Komatsu; Shinsuke Iida; Kazunori Imada; Takashi Uchiyama; Shiro Akinaga; Kenya Shitara; Ryuzo Ueda
Journal:  Clin Cancer Res       Date:  2010-02-16       Impact factor: 12.531

Review 5.  Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells.

Authors:  Tsvee Lapidot; Isabelle Petit
Journal:  Exp Hematol       Date:  2002-09       Impact factor: 3.084

6.  Circular CCR5 peptide conjugates and uses thereof (WO2008074895).

Authors:  Maja A Sommerfelt
Journal:  Expert Opin Ther Pat       Date:  2009-09       Impact factor: 6.674

7.  Generation of polyclonal antibodies directed against G protein-coupled receptors using electroporation-aided DNA immunization.

Authors:  Suzanne J F Kaptein; Joanne Jungscheleger-Russell; Pilar Martínez-Martínez; Patrick S Beisser; Hilde Lavreysen; Annelies Vanheel; Mark H De Baets; Cathrien A Bruggeman; Cornelis Vink; Mario Losen
Journal:  J Pharmacol Toxicol Methods       Date:  2007-12-03       Impact factor: 1.950

8.  Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73.

Authors:  C Théry; A Regnault; J Garin; J Wolfers; L Zitvogel; P Ricciardi-Castagnoli; G Raposo; S Amigorena
Journal:  J Cell Biol       Date:  1999-11-01       Impact factor: 10.539

9.  HIV blocking antibodies following immunisation with chimaeric peptides coding a short N-terminal sequence of the CCR5 receptor.

Authors:  Benjamin M Chain; Mahdad Noursadeghi; Michelle Gardener; Jhen Tsang; Edward Wright
Journal:  Vaccine       Date:  2008-08-31       Impact factor: 3.641

10.  Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats.

Authors:  Ruben Nogueiras; Christelle Veyrat-Durebex; Paula M Suchanek; Marcella Klein; Johannes Tschöp; Charles Caldwell; Stephen C Woods; Gabor Wittmann; Masahiko Watanabe; Zsolt Liposits; Csaba Fekete; Ofer Reizes; Francoise Rohner-Jeanrenaud; Matthias H Tschöp
Journal:  Diabetes       Date:  2008-08-20       Impact factor: 9.461

View more
  70 in total

1.  IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5-8, 2011, San Diego, CA.

Authors:  Johan Nilvebrant; D Cameron Dunlop; Aroop Sircar; Thierry Wurch; Emilia Falkowska; Janice M Reichert; Gustavo Helguera; Emily C Piccione; Simon Brack; Sven Berger
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

2.  Structural insights into the extracellular recognition of the human serotonin 2B receptor by an antibody.

Authors:  Andrii Ishchenko; Daniel Wacker; Mili Kapoor; Ai Zhang; Gye Won Han; Shibom Basu; Nilkanth Patel; Marc Messerschmidt; Uwe Weierstall; Wei Liu; Vsevolod Katritch; Bryan L Roth; Raymond C Stevens; Vadim Cherezov
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-17       Impact factor: 11.205

3.  Drug discovery: Structure-led design.

Authors:  Monica Hoyos Flight
Journal:  Nature       Date:  2013-10-17       Impact factor: 49.962

4.  An improved and robust DNA immunization method to develop antibodies against extracellular loops of multi-transmembrane proteins.

Authors:  Meredith Hazen; Sunil Bhakta; Rajesh Vij; Steven Randle; Dara Kallop; Vicki Chiang; Isidro Hötzel; Bijay S Jaiswal; Karen E Ervin; Bing Li; Robby M Weimer; Paul Polakis; Richard H Scheller; Jagath R Junutula; Jo-Anne S Hongo
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

Review 5.  Overcoming hurdles in developing successful drugs targeting chemokine receptors.

Authors:  Thomas J Schall; Amanda E I Proudfoot
Journal:  Nat Rev Immunol       Date:  2011-04-15       Impact factor: 53.106

Review 6.  Opportunities for therapeutic antibodies directed at G-protein-coupled receptors.

Authors:  Catherine J Hutchings; Markus Koglin; William C Olson; Fiona H Marshall
Journal:  Nat Rev Drug Discov       Date:  2017-07-14       Impact factor: 84.694

7.  Phage display and hybridoma generation of antibodies to human CXCR2 yields antibodies with distinct mechanisms and epitopes.

Authors:  Christine J Rossant; Danielle Carroll; Ling Huang; John Elvin; Frances Neal; Edward Walker; Joris J Benschop; Eldar E Kim; Simon T Barry; Tristan J Vaughan
Journal:  MAbs       Date:  2014       Impact factor: 5.857

8.  A cell-cell interaction format for selection of high-affinity antibodies to membrane proteins.

Authors:  Zhuo Yang; Yue Wan; Pingdong Tao; Min Qiang; Xue Dong; Chih-Wei Lin; Guang Yang; Tianqing Zheng; Richard A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-08       Impact factor: 11.205

9.  A combination of in vitro techniques for efficient discovery of functional monoclonal antibodies against human CXC chemokine receptor-2 (CXCR2).

Authors:  Ronald S Boshuizen; Catherine Marsden; Johan Turkstra; Christine J Rossant; Jerry Slootstra; Clive Copley; Klaus Schwamborn
Journal:  MAbs       Date:  2014       Impact factor: 5.857

10.  Generation and characterization of rendomab-B1, a monoclonal antibody displaying potent and specific antagonism of the human endothelin B receptor.

Authors:  Bertrand Allard; Anne Wijkhuisen; Aurélie Borrull; Frédérique Deshayes; Fabienne Priam; Patricia Lamourette; Frédéric Ducancel; Didier Boquet; Jean-Yves Couraud
Journal:  MAbs       Date:  2012-12-05       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.